A privately-held business located in Valladolid.

AMRI buys Gadea Pharmaceutical Group for $174 million AMRI today announced that it has acquired all of the outstanding shares of Gadea Pharmaceutical Group, a privately-held business located in Valladolid, Spain, focusing on technically complex active pharmaceutical ingredients and finished medication product håndkøb ed behandling . The purchase price was $174 million, like the issuance of 2.2 million shares of common stock to Gadea's owners, valued at $43.8 million, with the total amount paid in cash and through the assumption of existing personal debt. ‘The acquisition of Gadea marks another milestone inside our organization's path towards becoming the preeminent provider of custom and complex drug development solutions and item to both branded and generic pharmaceutical sector,’ said William S.